

Article

The influence of the LINC00961/SPAAR locus loss on murine development, myocardial dynamics, and cardiac response to myocardial infarction

Ana-Mishel Spiroski^{1#}, Rachel Sanders^{1#}, Marco Meloni¹, Ian R. McCracken¹, Adrian Thomson²,

Mairi Brittan¹, Gillian A. Gray¹, Andrew H. Baker^{1*}

¹ University/BHF Centre for Cardiovascular Science, Queens Medical Research Institute, University of Edinburgh, EH16 4TJ, UK.

² Edinburgh Preclinical Imaging, Edinburgh Preclinical Imaging, BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom

Authors have contributed equally

* Correspondence: Andrew H Baker, University of Edinburgh, Centre for Cardiovascular Sciences, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh UK, EH16 4TJ, Tel: 0131 24 26728, Email: Andy.Baker@ed.ac.uk

Abstract: Long non-coding RNAs (lncRNAs) have structural and functional roles in development and disease. We have previously shown that the LINC00961/SPAAR locus regulates endothelial cell function, and that both the lncRNA and micropeptide counter-regulate angiogenesis. To assess human cardiac cell SPAAR expression we mined a publicly available scRNASeq dataset and confirmed LINC00961 locus expression and hypoxic response in a murine endothelial cell line. We investigated post-natal growth and development, basal cardiac function, the cardiac functional response and tissue-specific response to myocardial infarction. To investigate the contribution of the LINC00961/SPAAR locus to determination of longitudinal growth, cardiac function, and response to myocardial infarction, we used a novel CRISPR/Cas9 locus knockout mouse line. Data mining suggested that SPAAR is predominantly expressed in human cardiac endothelial cells and fibroblasts, while murine LINC00961 expression is hypoxia-responsive in mouse endothelial cells. LINC00961^{-/-} mice displayed a sex-specific delay in longitudinal growth and development, smaller left ventricular systolic and diastolic areas and volumes, and greater risk area following myocardial infarction compared with wildtype littermates. These data suggest a role for the LINC00961/SPAAR locus in cardiac endothelial cell and fibroblast cell function and hypoxic-response, and in growth and development, and basal cardiovascular function in adulthood.

Keywords: lncRNA; LINC00961; SPAAR; scRNASeq; CRISPR/Cas9; cardiovascular physiology; fetal growth restriction; myocardial infarction

1. Introduction

Over 17 million worldwide deaths annually are due to cardiovascular diseases (CVD). [1] With no clinically utilised therapeutics available to reverse the disease process, management focuses on reducing risk factors that exacerbate the “silent symptoms” which contribute to ischaemic diseases of the heart and vasculature. Myocardial infarction (MI), which causes a prolonged lack of blood flow to the heart muscle, ultimately resulting in tissue necrosis and formation of a fibrotic scar, is one such disease. Whilst an MI shortens a patient’s life expectancy by >16 years,[2,3] greater acute survival rates increases the incidence of subsequent heart failure. In concert with higher worldwide life expectancies

and burgeoning increases in CVD risk factors, the economic and social burden of disease is ever-increasing. Investigating the underlying mechanisms which contribute to cardiovascular dysfunction and identifying potential therapeutic targets provides the most impactful opportunity for reducing the compounding costs of CVD.

As approximately 98% of the human genome is not protein coding yet is actively transcribed into RNA [4], non-coding RNAs (ncRNA) provide a possible target to investigate both their physiological relevance and therapeutic capacity as novel interventional approaches. Long non-coding RNAs (lncRNAs) can be within a known protein-coding gene (intronic) and over-lapping with another gene (sense-overlapping), antisense to a gene they are likely to regulate (present on the opposite DNA strand, sequence overlapping), or bi-directional to a gene they likely regulate (present on the opposite DNA strand, sequences not over-lapping). LncRNAs located between neighbouring protein-coding genes are termed long intergenic non-coding RNA (lincRNA). Various lincRNAs have been reported to contribute to cardiovascular biology, with their functions contributing to embryological heart development, cardiovascular cell commitment, cell migration, smooth muscle cell (SMC) phenotype-switching, vascular endothelial cell (EC) commitment and angiogenesis.[5-10]

LINC00961, a lincRNA located on human chromosome 9 at p13.3 (has 4 predicted transcripts with 1 predicted to undergo non-sense mediated decay (http://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000235387;r=9:35909490-35937153)). The locus is 1557 base pairs (bp) and contains 2 exons, of which exon 2 encodes the 75 amino acid micropeptide previously termed small regulatory polypeptide of amino acid response (SPAAR) by Matsumoto and colleagues, who identified 2 potential transcription start sites.[11] The mouse homologue (previously 5430416O09Rik) maps to chromosome 4 with 65.33% amino acid sequence conservation. Although greater conservation is observed between humans and non-human primates, the mouse and human locus is conserved in synteny with many of the same neighbouring protein coding genes. Interestingly, Di Salvo and colleagues show a 1.4 log₂ (fold change) in the right ventricle of heart failure patients compared to healthy donor controls.[12] Additionally, LINC00961 is expressed in highly vascular tissues such as the kidney, lungs, and placenta, and SPAAR deletion results in a 15.3-fold increase in LINC00961 locus expression in the murine heart.[11]

LINC00961 has been identified in multiple disease pathways associated with cardiovascular dysfunction. Wu and colleagues recently reported that LINC00961 is downregulated in patients with coronary artery disease (CAD) and in APOE^{-/-} mice.[13] In response to hypoxia, the H9C2 rat cardiomyoblast cell line demonstrates increased signal transducer and activator of transcription 1 (STAT1) interaction with the LINC00961 promoter and subsequent LINC00961 expression.[14] Downstream phosphorylation of phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), and glycogen synthase kinase-3β (GSK3β) were also inhibited. Activation of this pathway has been implicated in abrogating the pathological remodelling of the heart post hypoxia/reperfusion injury,[15] suggesting LINC00961's potential contribution to cardiomyocyte maintenance. Additionally, we have previously demonstrated that the LINC00961 locus directly regulates EC function, with SPAAR and LINC00961 counter-regulating angiogenesis *in vitro* and evidenced in a murine hindlimb ischaemia model of critical limb ischaemia.[16] In our previous work, we showed that LINC00961 binds the actin-binding protein thymosin beta-4x, which is involved in regulating cytoskeletal dynamics, angiogenesis and cell migration,[17] while SPAAR binds the actin-binding protein spectrin repeat containing nuclear envelope protein 1 (SYNE1/NESPRIN-1), which is highly expressed in cardiomyocytes.[18] These initial data suggest the importance of the LINC00961/SPAAR locus in cellular maintenance and response to environmental insult. However, the cardiac effects of LINC00961 locus knockout (KO) *in vivo* are still unknown. Therefore, we investigated the expression of SPAAR with single cell RNA sequencing (scRNAseq) data mining of human cardiac cell populations, the expression of the LINC00961 locus in a mouse endothelial-like cell line, and the effects of CRISPR/Cas9 LINC00961 locus deletion on murine growth and development, basal cardiac function, risk area following acute cardiac ischaemia, and physiological function following 7 days chronic cardiac ischaemia in a surgical model of MI.

2. Results

2.1. Human cardiac SPAAR expression and the endothelial cell LINC00961 response to hypoxia

Data mining revealed SPAAR expression primarily in human cardiac endothelial cells and fibroblasts (Figure 1A-B). LINC00961 expression is significantly reduced in murine bEnd.3 cells following 24- and 48-hours hypoxia (1% O₂) exposure compared with cells cultured in normoxia (5% O₂) (Figure 1C-D).




Figure 1. Human cardiac SPAAR expression and LINC00961 response to hypoxia. Uniform manifold approximation and projection for dimension reduction (UMAP) visualisation of human cardiac EC, fibroblast (FB), pericyte (PC), SMC, cardiomyocyte (CMC), adipocyte, neuronal cell, myeloid and lymphoid fraction [19] (A), and (B) SPAAR expression in human cardiac cell populations. LINC00961 expression is reduced in bEnd.3 mouse cells following 24-hours (A, black n=3) and 48-hours (B, black n=3) exposure to hypoxia (1% O₂) compared with bEnd.3 cells cultured in normoxia (5% O₂) collected in parallel (both, n=3). Student t-test. Data are mean \pm SEM. * p<0.05, ** p<0.01.

2.2. Post-weaning growth and development

Whilst there was no effect of genotype on female weight gain post-weaning (Figure 2A), longitudinal weight gain was reduced in male LINC00961^{-/-} mice (Figure 2B). There was an effect of sex and genotype on adult body weight, and a sex x genotype interaction, with male LINC00961^{-/-} mice attaining a lower adult weight (Table 1). Male LINC00961^{-/-} mice also had a greater brain to body weight ratio at adulthood.




Figure 2. Post-weaning growth by sex. Weight gain from weaning (3 weeks) to 9 weeks of age in females (A: WT, white, n=2-12; KO, black, n=8-13) and males (B: WT, white, n=6-11; KO, black, n=2-7); 2-way ANOVA. Mean +/- SEM. * p<0.05, **** p<0.0001, ns=not significant.

Table 1. Adult post-mortem organ weights

	Female		Male		Significance (p)		
	WT n=9	KO n=9	WT n=10	KO n=9	Sex	Genotype	Interaction
Weight (g)	20.8±0.9	20.9±0.5	27.1±0.6	23.7±0.9	0.01	0.03	0.02
Brain (mg)	443.9±8.8	428.4±10.6	450.7±5.3	435.5±12.5	ns	ns	ns
Brain:Body weight (mg/g)	21.5±0.5	20.5±0.5	16.7±0.4	18.5±0.5	0.01	ns	0.009
Heart (mg)	124.2±7.2	125.7±9.6	137.0±6.3	115.2±6.6	ns	ns	ns
Heart:Body weight (mg/g)	6.0±0.4	6.1±0.4	5.0±0.3	4.9±0.3	0.03	ns	ns
Lungs, total (mg)	167.7±16.5	147.1±7.4	148.0±3.6	139.9±4.9	ns	ns	ns
Lungs:Body weight (mg/g)	7.5±0.3	7.1±0.3	5.5±0.2	5.9±0.3	0.01	ns	ns
Liver (mg)	1,212±64	1,104±34	1,111±71	1,174±69	ns	0.004	ns
Liver:Body weight (mg/g)	58.4±2.5	53.2±2.5	53.5±2.4	49.6±2.5	ns	ns	ns
Spleen, total (mg)	88.3±5.8	88.0±3.8	84.9±4.3	80.3±8.6	ns	ns	ns
Spleen:Body weight (mg/g)	4.2±0.2	4.2±0.2	3.1±0.2	3.4±0.2	0.009	ns	ns
Soleus, total (mg)	6.4±0.4	6.4±0.6	8.6±0.6	8.1±0.8	ns	ns	ns
Soleus:Body weight (mg/g)	0.31±0.02	0.31±0.03	0.32±0.02	0.34±0.03	ns	ns	ns
	WT n=5	KO n=8	WT n=10	KO n=8	Sex	Genotype	Interaction
Nose to anus (mm)	79.5±1.5	79.7±1.1	82.3±1.1	79.0±0.8	ns	ns	ns
Head length (mm)	25.0±0.6	26.7±0.3	26.4±0.2	26.5±0.6	ns	0.006	ns
Biparietal diameter (mm)	11.6±0.2	11.2±0.2	11.8±0.1	11.7±0.2	ns	ns	ns
Tibia length (mm)	15.4±1.1	18.4±0.7	17.5±0.5	17.0±0.4	ns	0.05	ns

Post-mortem organ weights were collected in female (WT, n=5-9; KO, n=8-9), and male (WT, n=10; KO, n=8-9) adults (9.7±0.3 and 9.9±0.3 weeks, respectively). Data are mean ± SEM. Statistical differences are indicated: main effect of sex; main effect of genotype, and sex x genotype interaction (Two-Way ANOVA with Tukey's post-hoc comparison).

2.3. Basal cardiac dimensions and function

Stroke volume (SV), ejection fraction (EF), fractional area change (FAC), and cardiac output (CO) were not different in WT and LINC00961^{-/-} mice (Figure 3A-D) at baseline. Adult LINC00961^{-/-} mice had significantly smaller left ventricular (LV) systolic and diastolic area, and lower end-systolic volume (ESV) and end-diastolic volume (EDV) (Figure 3E-H). Mitral valve function was not different in KO compared with WT mice (data not shown).




Figure 3. Basal cardiac dimensions and function by ultrasound echocardiography. SV (A), EF (B), FAC (C), CO (D), left ventricular systolic (E) and diastolic (F) areas, ESV (G) and EDV (H) in 8-week-old female WT (white, n=14) and KO (black, n=14) mice. Student t-test. Data are mean \pm SEM. * p<0.05, ** p<0.01.

2.4. Acute myocardial risk area

There was a significant increase in risk area 30 minutes after left anterior descending (LAD) coronary artery occlusion (~17%, $p<0.01$) in adult male LINC00961^{-/-} compared with WT mice (Figure 4A-B).




Figure 4. LINC00961 knockdown increases area at risk of myocardial infarction. (A) Myocardial infarction risk area (pink and white) relative to total heart area (blue, pink and white) in heart tissue collected 30 minutes after LAD coronary artery occlusion in 9-week-old male mice. B Individual (left) and mean areas at risk in WT (white) and KO (black) mice (both $n=6$). Student t-test. Data are mean \pm SEM. ** $p<0.01$.

2.5. Cardiac function following surgically induced myocardial infarction

There was no difference between WT and LINC00961^{-/-} mice in SV, EF, FAC, CO, ESV or EDV at 7-days post-MI (Figure 5A-F).




Figure 5. Cardiac dimensions and function following MI. SV (A), EF (B), FAC (C), CO (D), left ventricular systolic (E) and diastolic (F) areas, ESV (G) and EDV (H) in WT (white, n=6) and KO (black, n=6) female mice 7 days and 14 days following chronic LAD occlusion. Student t-test. Data are mean \pm SEM.

3. Discussion

We show that LINC00961^{-/-} reduces adult LV area, ESV and EDV, suggesting an overall reduction in LV size, and greater risk area following MI. We have previously reported that LINC00961 locus CRISPR/Cas9 KO reduces alpha-smooth muscle actin (α SMA) cell-density in the mouse hindlimb skeletal muscle without altering capillary density.[16] Global dysfunction in EC endowment resulting in compromised development of the vascular network could limit the capacity for myocardial growth and the maintenance of functional myocardium throughout life.[20] Reduced LV volume independent of adult size in LINC00961^{-/-} mice suggests that the vascular influence on cardiac development requires further investigation. Regardless, an appropriate relative heart size and adequate basal cardiac function suggests that at this relatively young age, the heart is able to adapt to reduced LV volumes and maintain physiological homeostasis.

The novel finding of asymmetric, delayed postnatal growth and a brain-sparing phenotype in male LINC00961^{-/-} offspring indicates that the reduced vascular endowment previously reported in adults likely compromises embryonic implantation, the development of fetal vasculature, and subsequent growth.[21,22] This fetal growth restriction (FGR) phenotype is the result of preferential shunting of blood away from peripheral organs in order to protect brain growth and development *in utero*. As inadequate endothelial endowment results in chronic fetal ischaemia and fetal oxygenation, the fetal adaptation to an inhospitable *in utero* environment results in the pathological programming of cardiovascular function.[23] Although females are relatively protected from environmental insults on the developing embryo [21], adult manifestations of hypoxic pregnancy include impaired ventricular relaxation, enhanced myocardial contractility, and cardiac sympathetic dominance, which contribute to maintained cardiac output.[23-28] Overall, these data suggest a role for the LINC00961/SPAAR locus in somatic growth and development, and adult cardiovascular function.

Establishment of an efficient microvascular network in order to supply blood flow matched to metabolic demand is necessary throughout the body; however, nowhere more so than in the continuously active myocardium. We show that human cardiac ECs and FBs express SPAAR, and that LINC00961 expression in murine endothelial-like cells is hypoxia responsive. These data suggest the LINC00961/SPAAR locus is expressed in basal conditions, and that regulation of the LINC00961 transcript is evident in response to environmental insults, such as those associated with pro-angiogenic states. We have previously reported that the LINC00961/SPAAR locus contributes to angiogenesis in the peripheral musculature, and here we show the potential for its influence on *in vivo* cardiovascular function and response to localised cardiac ischaemia. Microvascular dysfunction is associated with cardiovascular dysfunction, accelerated pathological processes, and increased mortality.[29,30] ECs contribute to the regulation of shear stress, permeable barrier maintenance, leukocyte extravasation, blood clotting, inflammation, vascular tone, extracellular matrix (ECM) deposition, and vasoconstriction and vasodilation.[31-34] By adapting to altered blood flow and composition, EC activation primes the tissue environment for coagulation, inflammation, and vasoconstriction, a necessary cascade for wound healing and repair.[31] Inadequate vascular endowment has the potential not only to influence cardiac function, but also the tissue response to pathological processes.

We show that the left ventricular risk area following an acute MI is greater in LINC00961^{-/-} mice compared to wildtype littermates. However, at 7-days post-LAD occlusion in an MI model, cardiac function in LINC00961^{-/-} was not different from wildtype littermates. These data suggest that the cardiac vascular network may be compromised, but the progression toward heart failure, with a significant ~40% reduction in ejection fraction, is not compounded by LINC00961^{-/-}. It has previously been reported that reduced coronary vascularity increases cardiac vulnerability to fibrosis.[35-37] Reduced blood flow to the functional myocardium compromises coronary flow reserve required during increased cardiovascular work and pathological conditions.[30,38] Future investigations on the microvascular network during the acute remodelling window post-MI will help identify the contribution of LINC00961 and SPAAR to extracellular matrix remodelling and the secretion of matrix metalloproteinases, fibronectin, and proteoglycans during cardiac scar maturation. As SPAAR expression has already been detected in the human heart,[39] it will be important to understand the

effect of the peptide specifically on cardiac function and whether this is counterbalanced by the LINC00961 transcript.

4. Materials and Methods

4.1. Ethical Approval

All animal procedures were performed at a University of Edinburgh Biomedical and Veterinary Sciences facility. This research was conducted in accordance with the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012, following ethical review by the University of Edinburgh Animal Welfare and Ethical Review Board (AWERB), under project (70/8933) and personal licenses held within the University of Edinburgh and conducted in accordance with ARRIVE guidelines.[40] To align with the National Centre for the Replacement, Refinement, & Reduction of Animals in Research (NC3Rs) principles, both male and female mice were used for this work.

4.2. Single Cell RNASeq Data Mining

Normalised SPAAR expression was visualized in the heart cell atlas dataset (www.heartcellatlas.org).[19]

4.3. *In vitro* Endothelial Cell Response to Hypoxia

Murine brain microvascular endothelial-like cell line bEnd.3 (ATCC) cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Life Technologies, USA) with 10% FBS, and 1% penicillin and streptomycin at 37°C and 5% CO₂. Cells were plated in 6 well plates and incubated overnight to allow to adhere. The media was replaced the following day, and cells were incubated in a hypoxic chamber (Coy Laboratory Products, USA) at 1% O₂ (5% CO₂ and 94% N₂) for 24 or 48 hours. Three biological replicates were collected for each timepoint and condition. Cells were lysed with QIAzol (QIAGEN, USA), RNA extracted and qRT-PCR run as previously described.[6,16]

4.4. Generation of Experimental Groups

The LINC00961 locus knock out (KO) mouse line was generated using CRISPR/Cas9 technology (gRNA, proximal: ATACACTCCTCGCTCAATGT; gRNA, distal: CGAGGCTACGCTGTCACTACT) on a C57BL/6nTAC genetic background by Taconic Biosciences (USA). KO and wild-type (WT) littermates were produced through heterozygous breeding, offspring ear clip samples were collected and genotyped by Transnetyx (USA), as previously described.[16] A subset of females (WT, n=2-12; KO, n=8-13) and males (B: WT, n=6-11; KO, n=2-7) were weighed weekly, from 3-9 weeks of age, culled by cervical dislocation, and tissues harvested at 9 weeks (female: WT and KO, both n=9; male: WT, n=10, KO n=9) to analyse longitudinal growth and adult organ size. Adult female mice were allocated to undergo cardiac ultrasound echocardiography at 8 weeks of age to assess basal cardiac function (WT and KO, both n=14), and a subset of these underwent surgical coronary artery ligation (CAL) to assess the *in vivo* physiological response to a heart failure procedure (WT and KO, both n=6). Adult male mice were allocated to undergo CAL (WT and KO, both n=6) to assess the *in vivo* cardiac response to acute cardiac ischaemia. Tissues from these offspring were utilised in other studies.

4.5. Cardiac Ultrasound Echocardiography

Basal cardiac function was acquired by ultrasound echocardiography with Doppler flow under isoflurane anaesthesia (4% induction, ~1.25% maintenance) on the Vevo 770 and Vevo 3100 preclinical imaging systems and analysed in Vevo 770 V3.0 and Vevo lab V3.2.6 image analysis software (FUJIFILM VisualSonics Inc Toronto Canada) following independent in-house confirmation of individual system analytic outcomes (data not shown). Post-CAL cardiac function (7-days) was acquired on a Vevo 3100. Left ventricle (LV) function was assessed with brightness mode (B-mode) with Doppler flow, and motion mode (M-mode) in parasternal long and short axes (as appropriate), and EKV, ECG-gated Kilohertz Visualization. All echocardiography analyses were blinded.

4.6. Acute Coronary Artery Ligation

Male mice at 8 weeks of age were anaesthetised with 70 mg·kg⁻¹ intraperitoneal pentobarbital sodium (Euthatal), intubated endotracheally, ventilated with 3 cm H₂O positive-end expiratory pressure, with ventilation ventilated at 110 breaths per minute (tidal volume dependent on weight, 125–150 µL). Mice were maintained on homeothermic heating pads (Physitemp, USA and depth of anaesthesia monitored with corneal and withdrawal reflexes. The CAL was conducted as previously

described.[41] Briefly, the heart was exposed via left sternal thoracotomy, the epicardium punctured to reveal the main branch of the LAD coronary artery, and the LAD occluded by looping a 7-0 prolene suture. Following 30 minutes ischaemia, the aorta was catheterised, the LAD suture loosened, and the mouse perfused with PBS. Following PBS perfusion, Evans blue dye was perfused, hearts collected, processed as previously described and stained with 2% triphenyltetrazolium chloride to assess the cardiac risk area and infarct area.[42]

4.7. Chronic Coronary Artery Ligation

Female mice at 8 weeks of age were anaesthetised with intraperitoneal 100 mg·kg⁻¹ ketamine (Velatar, Boehringer Ingelheim) + 10 mg·kg⁻¹ xylazine (Rompun, 2%, Bayer), intubated endotracheally, ventilated with 3 cm H₂O positive-end expiratory pressure, with ventilated at 110 breaths per minute (tidal volume dependent on weight, 125–150 µL). Eye lubricant (Laci-Lube Eye Ointment 5g, Allergan) and mice were maintained on homeothermic heating pads (Physitemp, USA) and depth of anaesthesia monitored with corneal and withdrawal reflexes. To induce chronic CAL, the heart was exposed via a left thoracotomy between the 2nd and 3rd ribs was performed by blunt dissection, the epicardium punctured to reveal the main branch of the LAD coronary artery, and the LAD permanently occluded with a 7-0 prolene suture (Henry Schein). After thoracic and skin closure with 6-0 prolene sutures (Henry Schein), the anaesthetic was reversed with 1.0 mg·kg⁻¹ subcutaneous atipamezole (Antisedan, Henry Schein) and 500 µL 0.9% sterile saline. Mice were provided with 0.20 mg·kg⁻¹ buprenorphine (Temgesic, Henry Schein) at the time of surgery, 24- and 48-hours post-op, and housed in individually ventilated cages in a heat cabinet for 24 hours to help maintain body temperature.

4.8. Statistical Analysis

Data analyses were blinded. Power calculations based on previous data sets were performed to determine the minimum sample size required to achieve statistical significance (p<0.05). Data were analysed in JMP 12 (SAS Institute Inc., USA). Distribution was verified with the Shapiro-Wilk test and non-parametric data were log transformed where necessary. Sex comparisons, and sex by genotype interactions were analysed by factorial analysis of variance (two-way ANOVA). Tukey's post hoc testing was conducted where appropriate. Data are presented as the mean ± SEM.

Author Contributions: Conceptualization, A.H.B, G.A.G., M.B., A.M.S., R.S; methodology, A.M.S., M.M., R.S.; formal analysis, A.M.S., R.S., I.R.M., A.T.; investigation, A.M.S., M.M. and R.S.; resources, A.H.B., G.A.G., A.M.S.; data curation, A.M.S., R.S.; writing—original draft preparation, A.M.S., R.S.; writing—review and editing, A.H.B., G.A.G., M.B., A.T., I.R.M., M.M., A.M.S., R.S.; visualization, A.M.S., I.R.M.; supervision, A.H.B., G.A.G., M.B., A.M.S., M.M.; project administration, A.M.S., R.S., M.M.; funding acquisition, A.H.B. All authors have read and agreed to the published version of the manuscript.

Funding: This project has received funding from the European Union's Horizon 2020 Programme for Research and Innovation (825670). The British Heart Foundation supported this work (Program grants: RG/14/3/30706 to A.H.B., and project grant and FS/17/27/32698 to A.H.B.). Professor Baker is supported by The British Heart Foundation Chair of Translational Cardiovascular Sciences (CH/11/2/28733), European Research Council (EC 338991 VASCMIR). A.H.B., M.B., and A.M.S. are supported by the BHF Centre for Vascular Regeneration (RM/17/3/33381), A.H.B. and M.B. are supported by the BHF Regenerative Medicine Centre (RM/13/2/30158). MB is supported by the British Heart Foundation (FS/16/4/31831).

Acknowledgments: We are grateful to the staff of the University of Edinburgh Biomedical and Veterinary Sciences for their exemplary technical assistance.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

AKT	Protein kinase B
αSMA	Alpha-smooth muscle actin
bEnd.3	Brain microvascular endothelial-like cell line
CAD	Coronary artery disease
CAL	Coronary artery ligation
CMC	Cardiomyocyte
CO	Cardiac output

CVD	Cardiovascular disease
EC	Endothelial cell
ECM	Extracellular matrix
EDV	End-systolic volume
EF	Ejection fraction
ESV	End-systolic volume
FB	Fibroblast
FAC	Fractional area change
FGR	Fetal growth restriction
GSK3B	Glycogen synthase kinase-3B
LAD	Left anterior descending coronary artery
lincRNA	Long intergenic non-coding RNA
lncRNAs	Long non-coding RNAs
LV	Left ventricle
MI	Myocardial infarction
MTORC1	Mammalian target of rapamycin complex 1
ncRNA	Non-coding RNA
PC	Pericyte
PI3K	Phosphorylation of phosphoinositide 3-kinase
SMC	Smooth muscle cell
SPAAR	Small regulatory polypeptide of amino acid response
STAT1	Signal transducer and activator of transcription 1
SV	Stroke volume

References

1. WHO. [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)). Available online: (accessed on 1 June 2020).
2. Benjamin, E.J.; Virani, S.S.; Callaway, C.W.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Chiuve, S.E.; Cushman, M.; Delling, F.N.; Deo, R., et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. *Circulation* **2018**, *137*, e67-e492, doi:10.1161/cir.0000000000000558.
3. Matsumura, Y.; Zhu, Y.; Jiang, H.; D'Amore, A.; Luketich, S.K.; Charwat, V.; Yoshizumi, T.; Sato, H.; Yang, B.; Uchibori, T., et al. Intramyocardial injection of a fully synthetic hydrogel attenuates left ventricular remodeling post myocardial infarction. *Biomaterials* **2019**, *217*, 119289, doi:10.1016/j.biomaterials.2019.119289.
4. Yoon, J.H.; Abdelmohsen, K.; Gorospe, M. Functional interactions among microRNAs and long noncoding RNAs. *Semin Cell Dev Biol* **2014**, *34*, 9-14, doi:10.1016/j.semcdedb.2014.05.015.
5. Ballantyne, M.D.; McDonald, R.A.; Baker, A.H. lncRNA/MicroRNA interactions in the vasculature. *Clin Pharmacol Ther* **2016**, *99*, 494-501, doi:10.1002/cpt.355.
6. Boulberdaa, M.; Scott, E.; Ballantyne, M.; Garcia, R.; Descamps, B.; Angelini, G.D.; Brittan, M.; Hunter, A.; McBride, M.; McClure, J., et al. A Role for the Long Noncoding RNA SENCR in Commitment and Function of Endothelial Cells. *Mol Ther* **2016**, *24*, 978-990, doi:10.1038/mt.2016.41.
7. Kurian, L.; Aguirre, A.; Sancho-Martinez, I.; Benner, C.; Hishida, T.; Nguyen, T.B.; Reddy, P.; Nivet, E.; Krause, M.N.; Nelles, D.A., et al. Identification of novel long noncoding RNAs underlying vertebrate cardiovascular development. *Circulation* **2015**, *131*, 1278-1290, doi:10.1161/circulationaha.114.013303.
8. Michalik, K.M.; You, X.; Manavski, Y.; Doddaballapur, A.; Zörnig, M.; Braun, T.; John, D.; Ponomareva, Y.; Chen, W.; Uchida, S., et al. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. *Circ Res* **2014**, *114*, 1389-1397, doi:10.1161/circresaha.114.303265.

9. Ounzain, S.; Burdet, F.; Ibberson, M.; Pedrazzini, T. Discovery and functional characterization of cardiovascular long noncoding RNAs. *J Mol Cell Cardiol* **2015**, *89*, 17-26, doi:10.1016/j.yjmcc.2015.09.013.

10. Wang, K.; Liu, F.; Zhou, L.Y.; Long, B.; Yuan, S.M.; Wang, Y.; Liu, C.Y.; Sun, T.; Zhang, X.J.; Li, P.F. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. *Circ Res* **2014**, *114*, 1377-1388, doi:10.1161/circresaha.114.302476.

11. Matsumoto, A.; Pasut, A.; Matsumoto, M.; Yamashita, R.; Fung, J.; Monteleone, E.; Saghatelyan, A.; Nakayama, K.I.; Clohessy, J.G.; Pandolfi, P.P. mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide. *Nature* **2017**, *541*, 228-232, doi:10.1038/nature21034.

12. Di Salvo, T.G.; Guo, Y.; Su, Y.R.; Clark, T.; Brittain, E.; Absi, T.; Maltais, S.; Hemnes, A. Right ventricular long noncoding RNA expression in human heart failure. *Pulm Circ* **2015**, *5*, 135-161, doi:10.1086/679721.

13. Wu, C.T.; Liu, S.; Tang, M. Downregulation of linc00961 contributes to promote proliferation and inhibit apoptosis of vascular smooth muscle cell by sponging miR-367 in patients with coronary heart disease. *Eur Rev Med Pharmacol Sci* **2019**, *23*, 8540-8550, doi:10.26355/eurrev_201910_19168.

14. Liu, S.; He, Y.; Shi, J.; Liu, L.; Ma, H.; He, L.; Guo, Y. STAT1-activated LINC00961 regulates myocardial infarction by the PI3K/AKT/GSK3 β signaling pathway. *J Cell Biochem* **2019**, *120*, 13226-13236, doi:10.1002/jcb.28596.

15. Arslan, F.; Lai, R.C.; Smeets, M.B.; Akeroyd, L.; Choo, A.; Aguor, E.N.; Timmers, L.; van Rijen, H.V.; Doevedans, P.A.; Pasterkamp, G., et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. *Stem Cell Res* **2013**, *10*, 301-312, doi:10.1016/j.scr.2013.01.002.

16. Spencer, H.L.; Sanders, R.; Boulberdaa, M.; Meloni, M.; Cochrane, A.; Spiroski, A.M.; Mountford, J.; Emanueli, C.; Caporali, A.; Brittan, M., et al. The LINC00961 transcript and its encoded micropeptide SPAAR regulate endothelial cell function. *Cardiovasc Res* **2020**.

17. Kuzan, A. Thymosin β as an Actin-binding Protein with a Variety of Functions. *Adv Clin Exp Med* **2016**, *25*, 1331-1336, doi:10.17219/acem/32026.

18. Zhou, C.; Rao, L.; Shanahan, C.M.; Zhang, Q. Nesprin-1/2: roles in nuclear envelope organisation, myogenesis and muscle disease. *Biochem Soc Trans* **2018**, *46*, 311-320, doi:10.1042/bst20170149.

19. Litviňuková, M.; Talavera-López, C.; Maatz, H.; Reichart, D.; Worth, C.L.; Lindberg, E.L.; Kanda, M.; Polanski, K.; Heinig, M.; Lee, M., et al. Cells of the adult human heart. *Nature* **2020**, 10.1038/s41586-020-2797-4, doi:10.1038/s41586-020-2797-4.

20. Goodwill, A.G.; Dick, G.M.; Kiel, A.M.; Tune, J.D. Regulation of Coronary Blood Flow. *Compr Physiol* **2017**, *7*, 321-382, doi:10.1002/cphy.c160016.

21. Hemberger, M.; Hanna, C.W.; Dean, W. Mechanisms of early placental development in mouse and humans. *Nature Reviews Genetics* **2020**, *21*, 27-43, doi:10.1038/s41576-019-0169-4.

22. Swanson, A.M.; David, A.L. Animal models of fetal growth restriction: Considerations for translational medicine. *Placenta* **2015**, *36*, 623-630, doi:10.1016/j.placenta.2015.03.003.

23. Giussani, D.A.; Camm, E.J.; Niu, Y.; Richter, H.G.; Blanco, C.E.; Gottschalk, R.; Blake, E.Z.; Horder, K.A.; Thakor, A.S.; Hansell, J.A., et al. Developmental programming of cardiovascular dysfunction by prenatal hypoxia and oxidative stress. *PLoS ONE* **2012**, *7*, e31017, doi:10.1371/journal.pone.0031017.

24. Kumar, P.; Morton, J.S.; Shah, A.; Do, V.; Sergi, C.; Serrano-Lominin, J.; Davidge, S.T.; Beker, D.; Levasseur, J.; Hornberger, L.K. Intrauterine exposure to chronic hypoxia in the rat leads to progressive diastolic function and increased aortic stiffness from early postnatal developmental stages. *Physiological Reports* **2020**, *8*, e14327, doi:10.14814/phy2.14327.

25. Kane, A.D.; Herrera, E.A.; Camm, E.J.; Giussani, D.A. Vitamin C prevents intrauterine programming of in vivo cardiovascular dysfunction in the rat. *Circulation Journal* **2013**, *77*, 2604-2611, doi:10.1253/circj.CJ-13-0311.

26. Lindgren, I.; Altimiras, J. Prenatal hypoxia programs changes in β -adrenergic signaling and postnatal cardiac contractile dysfunction. *American Journal of Physiology - Regulatory, Integrative and Comparative Physiology* **2013**, *305*, R1093-1101, doi:10.1152/ajpregu.00320.2013.

27. Hauton, D.; Ousley, V. Prenatal hypoxia induces increased cardiac contractility on a background of decreased capillary density. *BMC Cardiovascular Disorders* **2009**, *9*, 1, doi:10.1186/1471-2261-9-1.

28. Niu, Y.; Kane, A.D.; Lusby, C.M.; Allison, B.J.; Chua, Y.Y.; Kaandorp, J.J.; Nevin-Dolan, R.; Ashmore, T.J.; Blackmore, H.L.; Derkx, J.B., et al. Maternal allopurinol prevents cardiac dysfunction in adult male offspring programmed by chronic hypoxia during pregnancy. *Hypertension* **2018**, *72*, 971-978, doi:10.1161/hypertensionaha.118.11363.

29. Pries, A.R.; Reglin, B. Coronary microcirculatory pathophysiology: can we afford it to remain a black box? *Eur Heart J* **2017**, *38*, 478-488, doi:10.1093/eurheartj/ehv760.

30. Charytan, D.M.; Skali, H.; Shah, N.R.; Veeranna, V.; Cheezum, M.K.; Taqueti, V.R.; Kato, T.; Bibbo, C.R.; Hainer, J.; Dorbala, S., et al. Coronary flow reserve is predictive of the risk of cardiovascular death regardless of chronic kidney disease stage. *Kidney Int* **2018**, *93*, 501-509, doi:10.1016/j.kint.2017.07.025.

31. Toborek, M.; Kaiser, S. Endothelial cell functions. Relationship to atherogenesis. *Basic Res Cardiol* **1999**, *94*, 295-314, doi:10.1007/s003950050156.

32. Davignon, J.; Ganz, P. Role of endothelial dysfunction in atherosclerosis. *Circulation* **2004**, *109*, Iii27-32, doi:10.1161/01.CIR.0000131515.03336.f8.

33. Hong, Y.K.; Harvey, N.; Noh, Y.H.; Schacht, V.; Hirakawa, S.; Detmar, M.; Oliver, G. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. *Dev Dyn* **2002**, *225*, 351-357, doi:10.1002/dvdy.10163.

34. Nakashima, Y.; Chen, Y.X.; Kinukawa, N.; Sueishi, K. Distributions of diffuse intimal thickening in human arteries: preferential expression in atherosclerosis-prone arteries from an early age. *Virchows Arch* **2002**, *441*, 279-288, doi:10.1007/s00428-002-0605-1.

35. Mohammed, S.F.; Hussain, S.; Mirzoyev, S.A.; Edwards, W.D.; Maleszewski, J.J.; Redfield, M.M. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. *Circulation* **2015**, *131*, 550-559, doi:10.1161/circulationaha.114.009625.

36. Campbell, D.J. Letter by Campbell Regarding Article, “Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction”. *Circulation* **2015**, *132*, e205-e205, doi:doi:10.1161/CIRCULATIONAHA.115.016091.

37. Xiao, Y.; Liu, Y.; Liu, J.; Kang, Y.J. The association between myocardial fibrosis and depressed capillary density in rat model of left ventricular hypertrophy. *Cardiovascular toxicology* **2018**, *18*, 304-311.

38. Kaijser, L.; Grubbström, J.; Berglund, B. Coronary circulation in acute hypoxia. *Clin Physiol* **1990**, *10*, 259-263, doi:10.1111/j.1475-097x.1990.tb00094.x.

39. van Heesch, S.; Witte, F.; Schneider-Lunitz, V.; Schulz, J.F.; Adami, E.; Faber, A.B.; Kirchner, M.; Maatz, H.; Blachut, S.; Sandmann, C.-L., et al. The Translational Landscape of the Human Heart. *Cell* **2019**, *178*, 242-260.e229, doi:https://doi.org/10.1016/j.cell.2019.05.010.

40. Kilkenny, C.; Browne, W.; Cuthill, I.C.; Emerson, M.; Altman, D.G. Animal research: Reporting in vivo experiments: The ARRIVE guidelines. *British Journal of Pharmacology* **2010**, *160*, 1577-1579, doi:10.1111/j.1476-5381.2010.00872.x.

41. Pell, V.R.; Spiroski, A.M.; Mulvey, J.; Burger, N.; Costa, A.S.H.; Logan, A.; Gruszczak, A.V.; Rosa, T.; James, A.M.; Frezza, C., et al. Ischemic preconditioning protects against cardiac ischemia reperfusion injury without affecting succinate accumulation or oxidation. *J Mol Cell Cardiol* **2018**, *123*, 88-91, doi:10.1016/j.jmcc.2018.08.010.
42. Chouchani, E.T.; Pell, V.R.; Gaude, E.; Aksentijević, D.; Sundier, S.Y.; Robb, E.L.; Logan, A.; Nadtochiy, S.M.; Ord, E.N.J.; Smith, A.C., et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. *Nature* **2014**, *515*, 431-435, doi:10.1038/nature13909.